Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain - Full Text View

Sponsored by:	Central South University
Information provided by:	Central South University
ClinicalTrials.gov Identifier:	NCT00451399

Purpose

Lifestyle intervention and certain medications have been shown to be effective for antipsychotic-induced weight gain, but no controlled studies have compared psychological and pharmacological therapies. We conducted a randomized, placebo-controlled study to test the efficacy of lifestyle intervention and metformin alone and in combination for antipsychotic-induced weight gain.

Condition	Intervention	Phase
Weight Gain	Drug: metformin Behavioral: lifestyle intervention	Phase IV

Drug Information available for: Metformin Metformin hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Efficacy Study
Official Title:	Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain: a Randomized Double-Blind Placebo- Controlled Comparison

Further study details as provided by Central South University:

Primary Outcome Measures:

body weight, body mass index, waist circumference, fasting glucose, fasting insulin, insulin resistance index

Estimated Enrollment:	128
Study Start Date:	October 2004
Study Completion Date:	December 2006

Detailed Description:

The study was designed as a double-blind randomized controlled trial, with research assessors and patients intended to be blind to the intervention status. The staff members performing the assessment were not involved in implementing any aspect of the intervention.128 patients were randomized to one of four 12-week individual treatments: metformin (750mg/day), placebo, lifestyle intervention plus metformin (750mg/day) or lifestyle intervention plus placebo. Medications were provided in double-blind fashion.The assessments include body weight, body mass index, waist circumference, fasting glucose, fasting insulin and insulin resistance index.

Eligibility

Ages Eligible for Study:	18 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

All participants met the Diagnostic and Statistical Manual of Mental Disorder-Fourth Edition (DSM-Ⅳ) criteria for schizophrenia27.
Participants were required to get weight gain more than 10% of their predrug body weight during less than 12 months of treatment with a targeted antipsychotic agent- clozapine, olanzapine, risperidone or sulpiride.
The duration of illness for all participants was less than 12 months.
Participants could be taking only one antipsychotic, whose dose had not changed by changed by more than 25% over the past 3 months.
All patients were stable outpatient.
The total score of Positive and Negative Syndrome Scale (PANSS) for all patients could be ≤60.
All participants were ensured that they could be carefully taken care of by one of their parents or guardians during the trial.

Exclusion Criteria:

Participants were excluded from the study if they had evidence of liver or renal diseases, pregnant or lactating women, cardiovascular diseases, hypertension or diabetes mellitus, specific systemic diseases, or conditions that limited their ability to perform the lifestyle modifications, such as arthritis, pulmonary diseases, neurological or dietary restrictions.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00451399

Locations

China, Hunan
Institute of Mental Health of The Second Xiangya Hospital, Central South University
Changsha, Hunan, China, 410011

Sponsors and Collaborators

Central South University

Investigators

Study Director:

Jingping Zhao, MD

Central South University

More Information

No publications provided by Central South University

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):

Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, He YQ, Liu YJ, Chen JD, Li LH. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008 Jan 9;299(2):185-93.

Study ID Numbers:	Jzhao
Study First Received:	March 22, 2007
Last Updated:	October 30, 2007
ClinicalTrials.gov Identifier:	NCT00451399 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Central South University:

Weight gain
antipsychotic
lifestyle interventions
metformin
antipsychotic-induced weight gain.

Study placed in the following topic categories:

Body Weight
Signs and Symptoms
Tranquilizing Agents
Hypoglycemic Agents
Metformin

Psychotropic Drugs
Body Weight Changes
Central Nervous System Depressants
Antipsychotic Agents
Weight Gain

Additional relevant MeSH terms:

Tranquilizing Agents
Metformin
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Depressants
Weight Gain
Antipsychotic Agents

Pharmacologic Actions
Body Weight
Signs and Symptoms
Hypoglycemic Agents
Therapeutic Uses
Body Weight Changes
Central Nervous System Agents

ClinicalTrials.gov processed this record on May 07, 2009